{"protocolSection":{"identificationModule":{"nctId":"NCT06475300","orgStudyIdInfo":{"id":"BL-B01D1-204-05"},"organization":{"fullName":"Sichuan Baili Pharmaceutical Co., Ltd.","class":"INDUSTRY"},"briefTitle":"A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors","officialTitle":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-20","studyFirstSubmitQcDate":"2024-06-20","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-25","lastUpdatePostDateStruct":{"date":"2024-06-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sichuan Baili Pharmaceutical Co., Ltd.","class":"INDUSTRY"},"collaborators":[{"name":"Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 Monoclonal Antibody in patients with locally advanced or metastatic non-small cell lung cancer, nasopharyngeal carcinoma and other solid tumors."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer","Nasopharyngeal Carcinoma","Solid Tumor"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":126,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BL-B01D1+PD-1 Monoclonal Antibody","type":"EXPERIMENTAL","description":"Participants receive BL-B01D1+PD-1 Monoclonal Antibody as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.","interventionNames":["Drug: BL-B01D1","Drug: PD-1 Monoclonal Antibody"]}],"interventions":[{"type":"DRUG","name":"BL-B01D1","description":"Administration by intravenous infusion for a cycle of 3 weeks.","armGroupLabels":["BL-B01D1+PD-1 Monoclonal Antibody"]},{"type":"DRUG","name":"PD-1 Monoclonal Antibody","description":"Administration by intravenous infusion for a cycle of 3 weeks.","armGroupLabels":["BL-B01D1+PD-1 Monoclonal Antibody"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Objective Response Rate (ORR)","description":"Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).","timeFrame":"Up to approximately 24 months"},{"measure":"Recommended Phase II Dose (RP2D)","description":"The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.","timeFrame":"Up to approximately 24 months"}],"secondaryOutcomes":[{"measure":"Progression-free survival (PFS)","description":"Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.","timeFrame":"Up to approximately 24 months"},{"measure":"Disease Control Rate (DCR)","description":"Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.","timeFrame":"Up to approximately 24 months"},{"measure":"Duration of Response (DOR)","description":"Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.","timeFrame":"Up to approximately 24 months"},{"measure":"Treatment Emergent Adverse Event (TEAE)","description":"TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.","timeFrame":"Up to approximately 24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Sign the informed consent form voluntarily and follow the protocol requirements;\n2. Any gender;\n3. Age: ≥18 years old and ≤75 years old;\n4. Expected survival time for 3 months or more;\n5. Patients with locally advanced or metastatic non-small cell lung cancer or nasopharyngeal carcinoma confirmed by histopathology and/or cytology;\n6. Subjects were able to provide 6-10 slides of archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 2 years;\n7. At least one measurable lesion meeting the RECIST v1.1 definition was required;\n8. ECOG 0 or 1;\n9. The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;\n10. No serious cardiac dysfunction, left ventricular ejection fraction 50% or higher;\n11. screening period not allowed within 14 days before a blood transfusion, are not allowed to use any cell growth factor, and/or liters of platelet medicine, organ function level must conform to the requirements;\n12. Coagulation function: international normalized ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5ULN;\n13. The urine protein + 2 or 1000 mg / 24 h or less or less;\n14. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum or urine must be negative for pregnancy, and must be non-lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.\n\nExclusion Criteria:\n\n1. Stage 1 EGFR-sensitive mutant non-small cell lung cancer patients with systemic chemotherapy; Stage 2 patients who had received previous systemic therapy;\n2. In the second stage queue one signed informed consent before gene sequencing report suggests patients such as mutation of ALK fusion;\n3. Anti-tumor therapy such as chemotherapy or biological therapy has been used within 4 weeks or 5 half-lives before the first dose; Mitomycin and nitrosoureas were administered within 6 weeks before the first dose; Fluorouracil class oral drugs, etc.;\n4. Serious heart disease;\n5. Long QT, complete left bundle branch block, III degree atrioventricular block; Serious arrhythmia;\n6. Active autoimmune and inflammatory diseases;\n7. Before the first delivery within 5 years diagnosed as other malignant tumor;\n8. Two antihypertensive drugs poorly controlled hypertension;\n9. Patients with poor glycemic control;\n10. With a history of ILD, current ILD or suspected suffering from such diseases during screening;\n11. Complicated with pulmonary diseases leading to severe respiratory function impairment;\n12. There is a lot of serous cavity effusion, or have a serous cavity effusion and has symptoms, or poorly controlled serous cavity effusion patients;\n13. Imaging studies suggest tumor has violated or package around the chest, neck, pharyngeal large blood vessels;\n14. Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;\n15. Active central nervous system of patients;\n16. For restructuring or human mouse chimeric antibody on study of humanized anti-platelet antibody has a history of allergies or allergic to BL - B01D1 any supplementary material composition of patients;\n17. Before transplant or allogeneic hematopoietic stem cell transplantation (Allo - HSCT);\n18. Human immunodeficiency virus antibody positive, active tuberculosis, active hepatitis B virus infection or active hepatitis C virus infection;\n19. Active infection requiring systemic therapy;\n20. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;\n21. Had participated in another clinical trial within 4 weeks before the first dose;\n22. Other conditions for trial participation were not considered appropriate by the investigator.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Sa Xiao, PHD","role":"CONTACT","phone":"15013238943","email":"xiaosa@baili-pharm.com"}],"overallOfficials":[{"name":"Li Zhang","affiliation":"Sun Yat-sen University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Sun Yat-sen University Cancer Center","city":"Guangzhou","state":"Guangdong","country":"China","contacts":[{"name":"Li Zhang","role":"CONTACT"}],"geoPoint":{"lat":23.11667,"lon":113.25}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000002277","term":"Carcinoma"},{"id":"D000008175","term":"Lung Neoplasms"},{"id":"D000002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D000077274","term":"Nasopharyngeal Carcinoma"},{"id":"D000009303","term":"Nasopharyngeal Neoplasms"}],"ancestors":[{"id":"D000009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000012142","term":"Respiratory Tract Neoplasms"},{"id":"D000013899","term":"Thoracic Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000008171","term":"Lung Diseases"},{"id":"D000012140","term":"Respiratory Tract Diseases"},{"id":"D000002283","term":"Carcinoma, Bronchogenic"},{"id":"D000001984","term":"Bronchial Neoplasms"},{"id":"D000010610","term":"Pharyngeal Neoplasms"},{"id":"D000010039","term":"Otorhinolaryngologic Neoplasms"},{"id":"D000006258","term":"Head and Neck Neoplasms"},{"id":"D000009302","term":"Nasopharyngeal Diseases"},{"id":"D000010608","term":"Pharyngeal Diseases"},{"id":"D000009057","term":"Stomatognathic Diseases"},{"id":"D000010038","term":"Otorhinolaryngologic Diseases"}],"browseLeaves":[{"id":"M5534","name":"Carcinoma","asFound":"Carcinoma","relevance":"HIGH"},{"id":"M11172","name":"Lung Neoplasms","asFound":"Lung Cancer","relevance":"HIGH"},{"id":"M5546","name":"Carcinoma, Non-Small-Cell Lung","asFound":"Non-Small Cell Lung Cancer","relevance":"HIGH"},{"id":"M1730","name":"Nasopharyngeal Carcinoma","asFound":"Nasopharyngeal Carcinoma","relevance":"HIGH"},{"id":"M12254","name":"Nasopharyngeal Neoplasms","asFound":"Cancer, Nasopharyngeal","relevance":"HIGH"},{"id":"M12320","name":"Neoplasms, Glandular and Epithelial","relevance":"LOW"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M14979","name":"Respiratory Tract Neoplasms","relevance":"LOW"},{"id":"M16658","name":"Thoracic Neoplasms","relevance":"LOW"},{"id":"M11168","name":"Lung Diseases","relevance":"LOW"},{"id":"M14977","name":"Respiratory Tract Diseases","relevance":"LOW"},{"id":"M5540","name":"Carcinoma, Bronchogenic","relevance":"LOW"},{"id":"M5260","name":"Bronchial Neoplasms","relevance":"LOW"},{"id":"M13517","name":"Pharyngeal Neoplasms","relevance":"LOW"},{"id":"M12962","name":"Otorhinolaryngologic Neoplasms","relevance":"LOW"},{"id":"M9348","name":"Head and Neck Neoplasms","relevance":"LOW"},{"id":"M12253","name":"Nasopharyngeal Diseases","relevance":"LOW"},{"id":"M13515","name":"Pharyngeal Diseases","relevance":"LOW"},{"id":"M12017","name":"Stomatognathic Diseases","relevance":"LOW"},{"id":"M12961","name":"Otorhinolaryngologic Diseases","relevance":"LOW"},{"id":"T4047","name":"Nasopharyngeal Carcinoma","asFound":"Nasopharyngeal Carcinoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC08","name":"Respiratory Tract (Lung and Bronchial) Diseases"},{"abbrev":"BC07","name":"Mouth and Tooth Diseases"},{"abbrev":"BC09","name":"Ear, Nose, and Throat Diseases"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000000906","term":"Antibodies"},{"id":"D000000911","term":"Antibodies, Monoclonal"}],"ancestors":[{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M4230","name":"Antibodies, Monoclonal","asFound":"Chemotherapy","relevance":"HIGH"},{"id":"M4225","name":"Antibodies","asFound":"Use","relevance":"HIGH"},{"id":"M10184","name":"Immunoglobulins","relevance":"LOW"},{"id":"M10201","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}